Adverse Events of Special Interest in Patients with Advanced Basal Cell Carcinoma Receiving Sonidegib: Long-Term 42-Month Results from the BOLT Study

Main Article Content

Alexander Guminski
Nicholas Squittieri
John T Lear

Keywords

Basal Cell carcinoma, Sonidegib, adverse effects

Abstract

Abstract not available.

References

1. Migden MR, et al. Lancet Oncol. 2015;16(6):716–28.

2. Odomzo (sonidegib) [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2017.

3. Australian Government Department of Health, ARTG 292262.

4. European Medicines Agency. Summary of Product Characteristics, WC500188762.

5. Swissmedic, Authorization Number 65065, 2015.

6. Migden MR, et al. J Clin Oncol. 2018; 36: Suppl abstr 9551.

7. Lear JT, et al. J Eur Acad Dermatol Venereol. 2018; 32 (3): 372–81.

8. Dummer R, et al. J Am Acad Dermatol. 2016; 75 (1): 113–25 e5.

9. Dummer R, et al. Br J Dermatol. 2019; 10.1111/bjd.18552.

10. Eisenhauer EA, et al. Eur J Cancer. 2009; 45 (2): 228–47.

11. World Health Organization. http://whqlibdoc.who.int/offset/WHO_OFFSET_48.pdf.

12. National Cancer Institute. Common Terminology Criteria for Adverse Events v4.03.

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)